Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FTX-101 Phase 1 SAD/MAD Study in Healthy Males
NCT06617546Phase 1Terminated
- Sponsor
- Find Therapeutics
- Start
- Oct 2024
- Primary completion
- Apr 2025
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of tasronetide in chronic optic neuropathy and multiple sclerosis (MS) (4 arms), sponsored by Find Therapeutics. Primary endpoints: Frequency of adverse events, Severity of adverse events and 7 more. Started Oct 2024; status: terminated.
02
Drugs
tasronetide
03
Conditions
chronic optic neuropathymultiple sclerosis (MS)
Beyond the preview
Go deeper on NCT06617546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06617546.